Biosimilar Renflexis PBS listing brings potential for health budget savings for Australia
MSD, the non-North America operating name of US pharma giant Merck & Co (NYSE: MRK), has announced the availability of biosimilar Renflexis (infliximab) on the Australian Pharmaceutical Benefits Scheme (PBS) from August 1.
This is a biosimilar of Remicade, which is health care giant Johnson & Johnson's (NYSE: JNJ) top seller, with 2016 sales totalling around $7 billion. Renflexis was co-developed with South Korean firm Samsung Bioepis.
Renflexis, which is the second infliximab biosimilar to be PBS listed, is indicated for the treatment of moderate to severe Crohn's disease and moderately severe to severe ulcerative colitis in adults and in children adolescents (6 to 17 years) who have had an inadequate response to conventional therapies, as well as several other inflammatory conditions. MSD’s biosimilar Brenzys (etanercept) was listed on the PBS on April 1, 2017
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze